First report of icatibant treatment in a pregnant patient with hereditary angioedema

H. Farkas, Kinga Viktória Kőhalmi, Nóra Veszeli, Ferenc Tóth, L. Varga

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hereditary angioedema resulting from C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant disorder, characterized by recurrent attacks of edema formation. The management of pregnant patients with C1-INH-HAE is often a challenge for the physician. There is limited experience with novel therapies. Plasma-derived nanofiltered C1-INH (pnfC1-INH) is the only recommended therapeutic option during pregnancy. In our 26-year-old female patient with type II C1-INH-HAE, pregnancy was confirmed in the sixth week of gestation. During this period, the patient received the bradykinin B2-receptor antagonist, icatibant, on five occasions, as acute treatment. She experienced 119 attacks, for which she received 108 vials of pnfC1-INH during her pregnancy. The patient gave birth to a healthy baby. No side effects were detected with either treatment. No reports have been published to date on multiple dosing with icatibant during the first trimester of pregnancy. This therapy proved effective and free of maternal or fetal adverse effects.

Original languageEnglish
Pages (from-to)1026-1028
Number of pages3
JournalJournal of Obstetrics and Gynaecology Research
Volume42
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Hereditary Angioedemas
Pregnancy
Therapeutics
First Pregnancy Trimester
Edema
Mothers
icatibant
Parturition
Physicians

Keywords

  • C1-inhibitor
  • hereditary angioedema
  • icatibant
  • pregnancy
  • treatment

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

First report of icatibant treatment in a pregnant patient with hereditary angioedema. / Farkas, H.; Kőhalmi, Kinga Viktória; Veszeli, Nóra; Tóth, Ferenc; Varga, L.

In: Journal of Obstetrics and Gynaecology Research, Vol. 42, No. 8, 01.08.2016, p. 1026-1028.

Research output: Contribution to journalArticle

Farkas, H. ; Kőhalmi, Kinga Viktória ; Veszeli, Nóra ; Tóth, Ferenc ; Varga, L. / First report of icatibant treatment in a pregnant patient with hereditary angioedema. In: Journal of Obstetrics and Gynaecology Research. 2016 ; Vol. 42, No. 8. pp. 1026-1028.
@article{4b49b9cf82e249d5a92175686d09ede1,
title = "First report of icatibant treatment in a pregnant patient with hereditary angioedema",
abstract = "Hereditary angioedema resulting from C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant disorder, characterized by recurrent attacks of edema formation. The management of pregnant patients with C1-INH-HAE is often a challenge for the physician. There is limited experience with novel therapies. Plasma-derived nanofiltered C1-INH (pnfC1-INH) is the only recommended therapeutic option during pregnancy. In our 26-year-old female patient with type II C1-INH-HAE, pregnancy was confirmed in the sixth week of gestation. During this period, the patient received the bradykinin B2-receptor antagonist, icatibant, on five occasions, as acute treatment. She experienced 119 attacks, for which she received 108 vials of pnfC1-INH during her pregnancy. The patient gave birth to a healthy baby. No side effects were detected with either treatment. No reports have been published to date on multiple dosing with icatibant during the first trimester of pregnancy. This therapy proved effective and free of maternal or fetal adverse effects.",
keywords = "C1-inhibitor, hereditary angioedema, icatibant, pregnancy, treatment",
author = "H. Farkas and Kőhalmi, {Kinga Vikt{\'o}ria} and N{\'o}ra Veszeli and Ferenc T{\'o}th and L. Varga",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/jog.13003",
language = "English",
volume = "42",
pages = "1026--1028",
journal = "Journal of Obstetrics and Gynaecology Research",
issn = "1341-8076",
publisher = "Blackwell Publishing Asia",
number = "8",

}

TY - JOUR

T1 - First report of icatibant treatment in a pregnant patient with hereditary angioedema

AU - Farkas, H.

AU - Kőhalmi, Kinga Viktória

AU - Veszeli, Nóra

AU - Tóth, Ferenc

AU - Varga, L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Hereditary angioedema resulting from C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant disorder, characterized by recurrent attacks of edema formation. The management of pregnant patients with C1-INH-HAE is often a challenge for the physician. There is limited experience with novel therapies. Plasma-derived nanofiltered C1-INH (pnfC1-INH) is the only recommended therapeutic option during pregnancy. In our 26-year-old female patient with type II C1-INH-HAE, pregnancy was confirmed in the sixth week of gestation. During this period, the patient received the bradykinin B2-receptor antagonist, icatibant, on five occasions, as acute treatment. She experienced 119 attacks, for which she received 108 vials of pnfC1-INH during her pregnancy. The patient gave birth to a healthy baby. No side effects were detected with either treatment. No reports have been published to date on multiple dosing with icatibant during the first trimester of pregnancy. This therapy proved effective and free of maternal or fetal adverse effects.

AB - Hereditary angioedema resulting from C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant disorder, characterized by recurrent attacks of edema formation. The management of pregnant patients with C1-INH-HAE is often a challenge for the physician. There is limited experience with novel therapies. Plasma-derived nanofiltered C1-INH (pnfC1-INH) is the only recommended therapeutic option during pregnancy. In our 26-year-old female patient with type II C1-INH-HAE, pregnancy was confirmed in the sixth week of gestation. During this period, the patient received the bradykinin B2-receptor antagonist, icatibant, on five occasions, as acute treatment. She experienced 119 attacks, for which she received 108 vials of pnfC1-INH during her pregnancy. The patient gave birth to a healthy baby. No side effects were detected with either treatment. No reports have been published to date on multiple dosing with icatibant during the first trimester of pregnancy. This therapy proved effective and free of maternal or fetal adverse effects.

KW - C1-inhibitor

KW - hereditary angioedema

KW - icatibant

KW - pregnancy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84978737296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978737296&partnerID=8YFLogxK

U2 - 10.1111/jog.13003

DO - 10.1111/jog.13003

M3 - Article

C2 - 27093898

AN - SCOPUS:84978737296

VL - 42

SP - 1026

EP - 1028

JO - Journal of Obstetrics and Gynaecology Research

JF - Journal of Obstetrics and Gynaecology Research

SN - 1341-8076

IS - 8

ER -